A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

Matthew S. Davids; Haesook T. Kim; Danielle M. Brander; Jad Bsat; Alexandra Savell; Karen Francoeur; Caron A. Jacobson; Samuel Y. Ng; Ann S. LaCasce; Ephraim P. Hochberg

doi:10.1182/blood.v130.suppl_1.496.496

A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

Identifier:nobleid.org/w1/20260515/AEC8CCCF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/AEC8CCCF.svg?ark=w1%2F20260515%2FAEC8CCCF)](https://nobleid.org/work/w1/20260515/AEC8CCCF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

Identifier:nobleid.org/w1/20260515/AEC8CCCF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/AEC8CCCF.svg?ark=w1%2F20260515%2FAEC8CCCF)](https://nobleid.org/work/w1/20260515/AEC8CCCF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work